Patent ID: 8507453

Claim:
A method for treatment of penicillin-resistant pneumococcal infection, which comprises administrating a pharmaceutically effective amount of a compound represented by the formula (I) or a pharmacologically acceptable salt thereof to a subject having penicillin-resistant pneumococcal infection: wherein, in the formula (I), R represents any one of a halogen atom, an azido group, Ra-Wa-, Rb-Wb-, Rc-Wc-, and RdRd′N—; the Wa represents one of —CO—O— and —CO—NH—; the Ra represents any one of a hydrogen atom, and a C 1-12 alkyl group, an unsaturated C 2-12 alkyl group, a C 6-14 aryl group, a 5- to 14-membered ring heteroaryl group, a C 7-16 aralkyl group, a 5- to 14-membered ring heteroaralkyl group, a C 1-12 alkoxy group, an unsaturated C 2-12 alkoxy group, a C 6-14 aryloxy group and a 5- to 14-membered ring heteroaryloxy group, which may each have a substituent; the Wb represents —O—; the Rb represents any one of a C 1-12 alkyl group, an unsaturated C 2-12 alkyl group, a C 6-14 aryl group, a 5- to 14-membered ring heteroaryl group, a C 7-16 aralkyl group, and a 5- to 14-membered ring heteroaralkyl group, which may each have a substituent; the Wc represents any one of —NH—CO—O—, —NH—CO—NH—, —NH—CS—NH—, and —S—; the Rc represents any one of a hydrogen atom, and a C 1-12 alkyl group, an unsaturated C 2-12 alkyl group, a C 6-14 aryl group, a 5- to 14-membered ring heteroaryl group, a C 7-16 aralkyl group and a 5- to 14-membered ring heteroaralkyl group, which may each have a substituent; and the Rd and the Rd′ may be the same or different and represent any one of a hydrogen atom, and a C 1-12 alkyl group, an unsaturated C 2-12 alkyl group, a C 6-14 aryl group, a 5- to 14-membered ring heteroaryl group, a C 7-16 aralkyl group, a 5- to 14-membered ring heteroaralkyl group, and a 3- to 8-membered ring nonaromatic heterocyclic group which the Rd and the Rd′ together form, each of which groups may have a substituent.